To compare the effectiveness of two TG2 inhibitors as anticancer drugs, the novel AA9 and the well-known NC9, we evaluated apoptosis after 48 h of exposure in three BC cell lines, MDA-MB-231, MDA-MB-436 and MDA-MB-468, which all have triple-negative phenotype but are affected by distinct mutations. Here, TGM2 is linked to breast cancer.